Arch Therapeutics’ (ARTH) Buy Rating Reiterated at HC Wainwright

Arch Therapeutics Inc (NASDAQ:ARTH)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday. They currently have a $3.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 276.07% from the company’s current price.

Other equities research analysts have also recently issued research reports about the company. Roth Capital set a $3.00 price target on Arch Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 25th. ValuEngine raised Arch Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 3rd. Zacks Investment Research raised Arch Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, June 1st. Finally, Ifs Securities reissued an “outperform” rating on shares of Arch Therapeutics in a research note on Tuesday, July 25th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $2.31.

Shares of Arch Therapeutics (NASDAQ:ARTH) traded up 0.44% during trading on Monday, reaching $0.80. The company’s stock had a trading volume of 117,996 shares. Arch Therapeutics has a 12 month low of $0.41 and a 12 month high of $0.89. The company’s 50 day moving average price is $0.74 and its 200 day moving average price is $0.60. The firm’s market cap is $117.62 million.

TRADEMARK VIOLATION NOTICE: This report was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at

About Arch Therapeutics

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Receive News & Ratings for Arch Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply